HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX)

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Investment analysts at HC Wainwright lowered their Q4 2026 earnings per share (EPS) estimates for BioNTech in a research report issued to clients and investors on Monday, June 16th. HC Wainwright analyst R. Burns now anticipates that the company will earn $0.88 per share for the quarter, down from their prior estimate of $0.90. HC Wainwright has a “Buy” rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share.

A number of other brokerages also recently issued reports on BNTX. Truist Financial reiterated a “buy” rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. BMO Capital Markets raised their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. The Goldman Sachs Group started coverage on BioNTech in a research report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 target price on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $137.86.

BioNTech Stock Performance

Shares of BNTX stock opened at $104.97 on Tuesday. The company has a market capitalization of $25.23 billion, a P/E ratio of -30.87 and a beta of 1.29. The business’s 50 day moving average is $101.59 and its two-hundred day moving average is $107.87. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Daiwa Securities Group Inc. increased its holdings in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after purchasing an additional 128 shares during the last quarter. Bank of New York Mellon Corp increased its stake in BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after acquiring an additional 150 shares during the last quarter. Probity Advisors Inc. increased its stake in BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock worth $224,000 after acquiring an additional 154 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in BioNTech by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock worth $227,000 after acquiring an additional 209 shares during the last quarter. Finally, Midwest Professional Planners LTD. increased its stake in BioNTech by 5.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock worth $462,000 after acquiring an additional 222 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.